China Drug Administration - Beijing Acctrue Technology Co., Ltd. was Founded in 2004, is a China’s leading company in building the ecological traceability system of the entire industry chain, takes one barcode for one item as the code, and relying on it
The World Health Organization (WHO) fully supports China's National Drug Administration's (NDA's) actions to withhold the problematic batches of rabies vaccine and ensure they are not placed on the market. During an unannounced inspection at the manufacturing site of Changchun Changsheng Life Scienc...
The China National Medical Products Administration or NMPA is the national regulatory body and competent authority for medical devices and in-vitro diagnostics (IVDs) in China. In 2018, the name was changed from the State Food and Drug Administration or SFDA to the NMPA. The NMPA is based in ...
Tian's efforts recently paid off. On March 15, China's National Medical Products Administration (NMPA) announced the approval of a new medicine developed by his company, a kind of kinase inhibitor that is helpful for combating melanoma. The inhibitor marks the first domestic drug of its kind ...
China's National Medical Products Administration approved its first treatment that specifically targets COVID-19. It uses a cocktail of two antibodies developed in China. Professor Zhang Linqi of Tsinghua University led the research team. Professor Zhang calls it cocktail therapy develop...
On March 30, 2020, China’s National Medical Products Administration (NMPA) published two long-awaited implementing rules under the most recent Drug Administration Law (DAL): the Drug Registration Regulation (DRR) and the Drug Manufacturing Regulation (DMR). They are effectiv...
On August 26, 2019, China's Standing Committee of National People's Congress (“NPC) adopted a significant revision of the Drug Administration Law (“DAL”). The newly adopted DAL (“Revised DAL”) will go into effect...
摘要: Background On May 8, 2018, the China National Medical Products Administration (NMPA) approved anlotinib, an orally administered anti-angiogenesis inhibitor, for the treatment of patients with advanced...关键词: Advanced non‐small cell lung cancer Anlotinib Anti‐angiogenesis Epidermal growth ...
KEYTRUDA Approved By China National Drug Administration (CNDA) in Five Months, Accelerating Availability of Anti-PD-1 Option to Advanced Melanoma Patients in China Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that KEYTRUDA®, Merck’s...
DRUG ADMINISTRATION LAW OF THE PEOPLE’S REPUBLIC OF CHINA （Adopted at the 7th Meeting of the Standing Committee of the Sixth National People’s Congress on September 20,1984, revised at the 20th Meeting of the Standing Committee of the Ninth National People’s Congress on February 28, 2001...